Completed PHASE1 INTERVENTIONAL 2-arm NCT05954169

Pharmacokinetic/Pharmacokinetic and Safety Studies of SHR4640 in Subjects With Moderate Renal Insufficiency and Healthy Subjects

A Single-dose, Open-label/Pharmacokinetic and Safety Study of SHR4640 in Subjects With Moderate Renal Insufficiency and Healthy Subjects

Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Conditions Hyperuricemia

Interventions SHR4640

Updated 5 times since 2023 Last updated: Jul 10, 2024 Started: Aug 7, 2023 Primary completion: Jul 1, 2024 Completion: Jul 1, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Hyperuricemia and is currently completed. Jiangsu HengRui Medicine Co., Ltd. leads this study, which shows 5 recorded versions since 2023 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Aug 2024 — Sep 2024 [monthly]

Completed PHASE1

Status: Recruiting → Completed
Jul 2024 — Aug 2024 [monthly]

Recruiting PHASE1
Sep 2023 — Jul 2024 [monthly]

Recruiting PHASE1

Status: Not Yet Recruiting → Recruiting
Aug 2023 — Sep 2023 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Jiangsu HengRui Medicine Co., Ltd.

Data source: Jiangsu HengRui Medicine Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Guangzhou, China